Botox sales, especially for aesthetic use, have been under pressure over the last few quarters due to economic uncertainties. Investors have also been concerned about potential market share losses to new entrants.
Tag Archive for: aesthetics
While reporting positive third-quarter financials, AbbVie announced it is halting the development of cedirogant (ABBV-157), while also providing updates on Skyrizi, Rinvoq and Humira.
